Carbamazepine Mucoadhesive Nanoemulgel (MNEG) as brain targeting delivery system via the olfactory mucosa

Drug Delivery

Volumn 19, Issue 1, 2012, Pages 58-67

  Samia, Omar ^a   Hanan, Refai ^b   Kamal, El Tahir ^c  

^a PRINCESS NOURAH BINT ABDULRAHMAN UNIVERSITY   (Saudi Arabia)

^b CAIRO UNIVERSITY   (Egypt)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

brain targeting; carbamazepine; delivery via olfactory mucosa; Nanoemulgel; uptake of drug by liposomes as biomembrane model

Indexed keywords

CARBAMAZEPINE; DRUG CARRIER; LABRASOL; LIPOSOME; MUCOADHESIVE NANOEMULGEL; OLEIC ACID; UNCLASSIFIED DRUG; XANTHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CLONIC SEIZURE; CONTROLLED STUDY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; DRUG UPTAKE; ELECTRIC SHOCK; IN VITRO STUDY; MOUSE; MUCOADHESION; NONHUMAN; OLFACTORY EPITHELIUM; PRIORITY JOURNAL;

ADHESIVES; ADMINISTRATION, INTRANASAL; ANIMALS; ANTICONVULSANTS; BRAIN; CARBAMAZEPINE; CATTLE; DRUG DELIVERY SYSTEMS; EMULSIONS; EPILEPSY; GELS; MICE; NANOTECHNOLOGY; OLFACTORY MUCOSA;

EID: 84855381477     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2011.644349     Document Type: Article

References (70)

1. Abrol S, Trehan A, Katare OP. 2005. Comparative study of diferent silymarin formulations: formulation, characterization and in vitro/in vivo evaluation. Curr Drug Deliv, 2, 45-51. (Pubitemid 40590920)
2. Aggarwal A, Kumar M, Faridi MM. 2005. Efect of carbamazepine on serum lipids and liver function tests. Indian Pediatr, 42(9), 913-918. (Pubitemid 41345646)
3. Akkar A, Müller RH. 2003. Formulation of intravenous carbamazepine emulsions by SolEmuls® technology. Eur J Pharm Biopharm, 55, 305-312. (Pubitemid 36561557)
4. Andrew GP, Laverty TP, Jones DS. 2009. Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm, 71(3), 505-518.
5. Banziger R, Hane D. 1967. Evalustion of a new convulsant for anticonvulsant screening. Archiv Int Pharmacodyn, 167, 245-249.
6. Becirevic-Lacan M, Jug M, Bacic-Vrca V, Cetina-Cizmek B. 2002. Development of o/w emulsion formulation for carbamazepine by using modifed cyclodextrins. Acta Pharm, 52, 149-159. (Pubitemid 35285062)
7. Belinsky SA, Walker VE, Maronpot RR, Swenberg JA, Anderson MW. 1987. Molecular dosimetry and DNA adduct formation and toxicity in rat nasal mucosa following exposure to the tobacco specifc nitrosamine 4-(N-methyl-N-nitrosamino) -1-(3-pyridyl)-1-butanone and their relationship to induction of neoplasia. Cancer Res, 47, 6058-6065. (Pubitemid 18018754)
8. Ch'ng HS, Park H, Kelly P, Robinoson JR. 1985. Bioadhesive polymers as platforms for oral controlled drug delivery II. Synthesis and evaluation of some swelling water-insoluble bioadhesive polymers. J Pharm Sci, 74, 339-405.
9. Chou KJ, Donovan MD. 1997. Distribution of antihistamines into the CSF following intranasal delivery. Biopharm Drug dispos, 18, 335-346 (Pubitemid 27241149)
10. Constantinides PP, Lambert KJ, Tustian AK, Schneider B, Lalji S, Ma W, Wentzel B, Kessler D, Worah D, Quay SC. 2000. Formulation development and antitumor activity of a flter-sterilizable emulsion of paclitaxel. Pharm Res, 17, 175-182. (Pubitemid 30158366)
11. Constantinides PP, Tustian A, Kessler DR. 2004. Tocol emulsions for drug solubilization and parenteral delivery. Adv Drug Deliv Rev, 56, 1243-1255. (Pubitemid 38510472)
12. Coviello T, Matricardi P, Marianecci C, Alhaique F. 2007. Polysaccharide hydrogels for modifed release formulations. J Control Rel, 119, 5-24. (Pubitemid 46561537)
13. Dahlin M, Bergman U, Jansson B, Björk E, Brittebo E. 2000. Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm Res, 17(6), 737-42.
14. Dangprasirt P, Pongwai S. 1998. Development of diclofnac sodium controlled release solid dispersion powders and capsules by freeze drying technique using ethylcellulose and chitosan as carriers. Drug Dev Ind Pharm, 24, 947-953. (Pubitemid 28470971)
15. D'Souza SS, DeLuca PP. 2006. Methods to assess in vitro drug release from injectable polymeric particulate systems. Pharm Res, 23, 460-474.
16. Edman P, Bjork E, Ryden L. 1992. Microspheres as a nasal delivery system for peptides. J Control Rel, 21, 165-172.
17. Eftaiha AF, Qinna N, Rashid IS, Al Remawi MM, Al Shami MR, Arafat TA, Badwan AA. 2010. Bioadhesive controlled metronidazole release matrix based on chitosan and xanthan gum. Mar Drugs, 8, 1716-1730.
18. Elshafeey AH, Bendas ER, Mohamed OH. 2009. Intranasal microemulsion of sildenafl citrate: In vitro evaluation and in vivo pharmacokinetic study in rabbits. AAPS Pharm Sci Tech, 10 (2), 361-367.
19. El Tahir KEH, Abdel-Kader M. 2008. Chemical and pharmacological study of Cymbopogon Proximus volatile oil. Res J Med Plants, 2(2), 52-60.
20. Fahr A, Seelig J. 2001. Liposomal formulations of Cyclosporin A: A biophysical approach to pharmacokinetics and pharmacodynamics. Crit Rev Ter Drug Carr Syst, 18(2), 141-172. (Pubitemid 32378146)
21. Fahr A, Reszka R, Seelig J. 1996. Paclitaxel partitioning into lipid bilayers. J Pharm Sci, 85, 228-231. (Pubitemid 26055806)
22. Fahr A, van Hoogevest P, May S, Bergstrand N, Leigh MLS. 2005. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: Consequences for drug delivery. Eur J Pharm Sci, 26, 251-265. (Pubitemid 41278632)
23. Garcia-Ochoa F, Santos VE, Casa JA, Gomez E. 2000. Xanthan gum: production, recovery, and properties. Biotechnol Adv, 18, 549-579. (Pubitemid 32122510)
24. Gasco MR. (1997). Microemulsions in the pharmaceutical feld: perspectives and applications," in Industrial Applications of Microemulsions, New York, marcel Dekker, 97-122.
25. Goodman LS, Gilman AG, Hardman JG, Limbird LE. (2001). Goodman & Gilman's, The pharmacological basis of therapeutics. New York: McGraw-Hill Book Co.
26. Grassi M, Coceani N, Magarotto L. 2000. Mathematical modeling of drug release from microemulsions: theory in comparison with experiments. J Colloid Interface Sci, 228, 141-150. (Pubitemid 30483383)
27. Graziadei PPC. 1973. Cell dynamics in the olfactory mucosa. Tissue and Cell, 5, 113-131.
28. Gu JM, Robinson JR, Leung SH. 1998. Binding of acrylic polymers to mucin/epithelial surfaces: structure-property relationships. Crit Rev Ter Drug Carr Syst, 5, 21-67.
29. Harding SE. 2006. Trends in mucoadhesive analysis. Trends Food Sci Tech, 17 (5), 255-262.
30. Henriksen I, Sande SA, Smistad G, Agren T, Karlsen J. 1995. In vitro evaluation of drug release kinetics from liposomes by fractional dialysis. Int J Pharm, 119, 231-238.
31. Herbette L, Rhodes DG, Preston Mason R. 1991. New approaches to drug design and delivery based on drug-membrane interactions. Drug Design Deliv, 7, 75-118.
32. Illum L. 2004. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol, 56(1), 3-17. (Pubitemid 38195323)
33. James O, McNamara. (2006). Pharmacotherapy of the epilepsies. In: Brunton LL, Lazo JS, Parker KL, ed. Goodman & Gilman's, The pharmacological basis of therapeutics. New York: McGraw-Hill, 12th ed, 501-525.
34. Kawakami K, Yoshikawa T, Moroto Y, Kanaoka E, Takahashi K, Nishihara Y, Masuda K. 2002. Microemulsion formulation for enhanced absorption of poorly soluble drugs II. In vivo study. J Control Rel, 81, 75-82. (Pubitemid 34454851)
35. Kelmann RG, Kuminek G, Teixeira HF, Koester LS. 2007. Carbamazepine parenteral nanoemulsions prepared by spontaneous emulsifcation process. Int J Pharm, 342(1-2), 231-239. (Pubitemid 47271896)
36. Kobayashi Y, Itai S, Yamamoto K. 2000. Pysicochemical propreties and bioavailability of carbamazepine polymorphs and dehydrate. Int J Pharm, 193, 137-146. (Pubitemid 30001856)
37. Kuminek G, Kratz JM, Ribeiro R, Kelmann RG, de Araújo BV, Teixeira HF, Simões CMO, Koester LS. 2009. Pharmacokinetic study of a carbamazepine nanoemulsion in beagle dogs. Int J Pharm, 378, 146-148.
38. Lawrence MJ, Rees GD. 2000. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev, 45, 89-121.
39. Mansur AT, Pekcan Yaar S, Göktay F. 2008. Anticonvulsant hypersensitivity syndrome: clinical and laboratory features. Int J Dermatol, 11, 1184-1189.
40. Mustafa G, Khan Z, Bansal T, Talegaonkar S. 2009. Preparation and Characterization of Oil in Water Nano-Reservoir Systems for Improved Oral Delivery of Atorvastatin. Curr Nanosci, 5, 428-440.
41. Needleman IG, Smales FC. 1995. In vitro assessment of bioadhesion for periodontal and buccal drug delivery. Biomaterials, 16, 617-624.
42. Newell BD, Moinfar M, Mancini AJ, Nopper AJ. 2009. Retrospective analysis of 32 pediatric patients with anticonvulsant hypersensitivity syndrome (ACHSS). Pediatr Dermatol, 26(5), 536-546.
43. Paget GE, Barnes JM. (1964). In: Evaluation of Drug Activities: Pharmacometrics. Laurence DR, Bacharach AL, eds. New York: Academic press, 135.
44. Paolino D, Ventura CA, Nisticò S, Puglisi G, Fresta M. 2002. Lecithin microemulsions for the topical administration of ketoprofen: percutaneous adsorption through human skin and in vivo human skin tolerability. Int J Pharm, 244(1-2), 21-31. (Pubitemid 35245443)
45. Parodi B, Russo E, Caviglioni G, Cafagi S, Bignardi G. 1996. Development and characterization of a buccoadhesive dosage from of oxycodone hydrochloride. Drug Dev Ind Pharm, 22, 445-450. (Pubitemid 26171575)
46. Peppas NA. 1985. Analysis of Fickian and non Fickian drug release from Polymers. Pharm Acta Helv, 60, 110-111.
47. Peppas NA, Buri PA. 1985. Surface, interfacial and molecular aspects of polymer bioadhesion on soft tissues. J Control Rel, 2, 257-275. (Pubitemid 16195943)
48. Punyapalakul P, Sitthisorn T. 2010. Removal of ciprofoxazin and carbamazepine by adsorption on functionalized mesoporous silicates. World Academy of Science, Engineering and Technology, 69, 546-550.
49. Puranam RS, McNamara K. 1999. Seizure disorder in mutant mice: relevance to human epilepsies. Curr Opin Neurobiol, 9, 281-287. (Pubitemid 29267597)
50. Ren-Qi Huang C. Hornes B, Mohammed I, Douglas D, Dewe CJA, Dillon GH. 2001. Pentylene tetrazole-induced inhibition of recombinant GABA receptors. Pharm Exp Ter, 298, 986-995.
51. Rojas-Barros P, De Haro A, Munoz J, Fernandez-Martinez JM. 2004. Isolation of a natural mutant in castor with high oleic/low ricinoleic acid content in the oil. Crop Sci, 44(1), 76-80. (Pubitemid 38051605)
52. Russell Y, Evans P, Dodd GH. 1989. Characterization of the total lipid and fatty acid composition of rat olfactory mucosa. J Lipid Res, 30, 877-884. (Pubitemid 19167309)
53. Sakane T, Akizuki T, Yamashita S, Sezaki H, Nadai T. 1994. Direct drug transport from the rat nasal cavity to the cerebrospinal fuid: the relation to the dissociation of the drug. J Pharm Pharmacol, 46(5), 378-379. (Pubitemid 24140941)
54. Schultz K, Mollgaard B, Frokjaer S, Larsen C. 1997. Rotating dialysis cell as in vitro release method for oily parenteral depot solutions. Int J Pharm, 157, 163-169. (Pubitemid 27471168)
55. Sethia S, Squillante E. 2002. Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method. J Pharm Sci, 91, 1948-1957. (Pubitemid 36254931)
56. Shafq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. 2007. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm, 66(2), 227-243. (Pubitemid 46667230)
57. Sintov AC, Botner S. 2006. Transdermal drug delivery using microemulsion and aqueous systems: infuence of skin storage conditions on the in vitro permeability of diclofenac from aqueous vehicle systems. Int J Pharm, 311, 55-62.
58. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. 1999. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm, 178(1), 55-65. (Pubitemid 29074407)
59. Sugano K. (2007). Artifcial membrane technologies to assess transfer and permeation of drugs in drug discovery. In: Taylor JB and Triggle DJ, eds. Comprehensive Medicinal Chemistry II, Volume 5: ADME-Tox Approaches. Japan: Pfzer Inc., Elsevier Ltd, 449
60. Sweetman SC. (2006). Martindale: The Complete Drug Reference. London: Pharmaceutical Press.
61. Syn WK, Naisbitt DJ, Holt AP, Pirmohamed M, Mutimer DJ. 2005. Carbamazepine-induced acute liver failure as part of the DRESS syndrome. Int J Clin Pract, (8), 988-991.
62. Talukdar MM, Michoel A, Rombaut P, Kinget R. 1996. Comparative study on xanthan gum and hydroxypropylmethylcellulose as matrices for controlled-release drug delivery. I. Compaction and in vitro drug release behaviour. Int J Pharm, 129, 233-241. (Pubitemid 26098739)
63. Torne RG, Frey WH II. 2001. Delivery of neurotrophic factors to the central nervous system: Pharmacokinetic considerations. Clin Pharmacokinet, 40(12), 907-946.
64. Ughini F, Andreazza IF, Ganter JLMS, Bresolin TMB. 2004. Evaluation of xanthan and highly substituted galactomannan from M. scabrella as a sustained release matrix. Int J Pharm, 271, 197-205 (Pubitemid 38210097)
65. Van Balen GP, Martinet CM, Caron G, Bouchard G, Reist M, Carrupt PA, Fruttero R, Gasco A, Testa B. 2004. Liposome/water lipophilicity: Methods, information content and pharmaceutical applications. Med Res. Rev, 24(3), 299-324. (Pubitemid 38490034)
66. Voudris KA, Attilakos A, Katsarou E, Garouf A, Dimou S, Skardoutsou A, Mastroyianni S. 2005. Early alteration in bone metabolism in epileptic children receiving carbamazepine monotherapy owing to the induction of hepatic drug-metabolizing enzymes. J Child Neurol, 20(6), 513-516. (Pubitemid 41015247)
67. Vyas TK, Babbar AK, Sharma RK, Singh S, Misra A. 2006. Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS Pharm Sci Tech,7(1), E8
68. White HS, Woodhead JH, Franklin MR, Swingered EA, Wolf HH. (1995). General principles: Experimental selection, quantifcation and evaluation of anti-epileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, eds. Anti-epileptic drugs. New York: Raven press Ltd., 99-122.
69. Yamaguchi T, Nishizaki K, Itai S, Hayashi H, Ohshima H. 1995. Physicochemical characterization of parenteral lipid emulsion: infuence of cosurfactants on focculation and coalescence. Pharm Res; 12, 1273-1278.
70. Zhang Q, Jiang X, Jiang W, Lu W, Su L, Shi Z. 2004. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efciency to the brain. Int J Pharm, 275, 85-96. (Pubitemid 38481522)